MedTrace Logo

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

NCT06888232 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2025-03-21

No results posted yet for this study

Summary

This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.

Conditions

Interventions

DRUG

Thalidomide

Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Muhammad Aslam, FCPS · Children's Hospital and institute of Child Health Multan, Punjab, Pakistan

  • Sara Rubab, FCPS · Children's Hospital and institute of Child Health Multan, Punjab, Pakistan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06888232 on ClinicalTrials.gov